[go: up one dir, main page]

IL114914A0 - Modulation of cellular activity - Google Patents

Modulation of cellular activity

Info

Publication number
IL114914A0
IL114914A0 IL11491495A IL11491495A IL114914A0 IL 114914 A0 IL114914 A0 IL 114914A0 IL 11491495 A IL11491495 A IL 11491495A IL 11491495 A IL11491495 A IL 11491495A IL 114914 A0 IL114914 A0 IL 114914A0
Authority
IL
Israel
Prior art keywords
modulation
cellular activity
cellular
activity
Prior art date
Application number
IL11491495A
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002131130A external-priority patent/CA2131130A1/en
Priority claimed from CA 2145605 external-priority patent/CA2145605A1/en
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of IL114914A0 publication Critical patent/IL114914A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/503Pyridazines; Hydrogenated pyridazines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11491495A 1994-08-30 1995-08-11 Modulation of cellular activity IL114914A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002131130A CA2131130A1 (en) 1994-08-30 1994-08-30 Modulation of cellular activity
CA 2145605 CA2145605A1 (en) 1995-03-27 1995-03-27 Modulation of cellular activity

Publications (1)

Publication Number Publication Date
IL114914A0 true IL114914A0 (en) 1995-12-08

Family

ID=25677464

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11491495A IL114914A0 (en) 1994-08-30 1995-08-11 Modulation of cellular activity

Country Status (9)

Country Link
EP (1) EP0778776A1 (en)
JP (1) JPH10504828A (en)
KR (1) KR970705401A (en)
CN (1) CN1130532A (en)
AP (1) AP618A (en)
AU (1) AU3159595A (en)
HU (1) HUT76846A (en)
IL (1) IL114914A0 (en)
WO (1) WO1996006622A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141076T3 (en) 1988-09-01 2000-03-16 Bayer Ag HUMAN RHINOVIRUS RECEPTOR PROTEIN INHIBITING VIRUS INFECTIVITY.
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
AU739601B2 (en) * 1991-07-03 2001-10-18 Meditech Research Limited Use of hyaluronan in gene therapy
AU727001B2 (en) * 1995-12-01 2000-11-30 Jagotec Ag Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
CA2166155C (en) * 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2205771C (en) * 1997-05-22 2002-05-14 Hyal Pharmaceutical Corporation Improved delivery of disease modifiers
DE59906391D1 (en) * 1998-12-23 2003-08-28 Esparma Gmbh AGENT FOR PROTECTING THE SKIN CONTAINING HYDROLYSED HYALURONIC ACID
AU773984B2 (en) * 1999-01-13 2004-06-10 Alchemia Oncology Pty Limited A composition and method for the enhancement of the efficacy of drugs
DK1140198T3 (en) 1999-01-13 2008-03-10 Alchemia Oncology Pty Ltd Use of hyaluronan in the manufacture of a drug for enhancing the efficacy of cytotoxic drugs
WO2001080899A2 (en) * 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
EP1311276A4 (en) * 2000-07-31 2007-09-12 Dermal Res Lab Inc Methods of preventing or treating diseases and conditions using complex carbohydrates
WO2003041723A1 (en) * 2001-11-12 2003-05-22 Reinmueller Johannes Pharmaceutical applications of hyaluronic acid preparations
CA2502363A1 (en) * 2002-11-12 2004-05-27 Omeros Corporation Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
ES2246695B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
JP5465431B2 (en) 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド Treatment protocol with hyaluronan
BRPI0615619A2 (en) 2005-09-07 2011-05-24 Alchemia Oncology Pty Ltd therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MX2009010400A (en) 2007-03-30 2010-02-18 Chu Sainte Justine Method of determining risk of scoliosis.
ES2385995B2 (en) 2011-01-10 2013-05-21 Universidade De Santiago De Compostela NANOCAPPSULES WITH POLYMER COVER
US9615750B2 (en) 2012-06-14 2017-04-11 Seno Medical Instruments, Inc. Methods and compositions for carrier agents and clearing agents used in optoacoustic imaging systems
FR2994846B1 (en) 2012-08-29 2014-12-26 Vivacy Lab COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE
FR3020570B1 (en) * 2014-04-30 2017-07-21 Pierre Fabre Dermo Cosmetique ASSOCIATION OF A HYALURONIC ACID AND A SULFATE POLYSACCHARIDE
WO2019199385A1 (en) 2018-04-13 2019-10-17 Carrier Corporation Method of defrosting a multiple heat absorption heat exchanger refrigeration system
CN120617530A (en) * 2018-04-18 2025-09-12 I.Com医疗有限责任公司 High molecular weight hyaluronic acid for enhanced epithelial survival and body surface reconstruction
CN109481693B (en) * 2018-12-14 2022-02-22 药大制药有限公司 A kind of hyaluronic acid-nonoxynol ether conjugate, preparation method and application
CN118063833B (en) * 2024-04-19 2024-06-28 四川兴泰普乐医疗科技有限公司 Micro-crosslinking sodium hyaluronate gel and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CH666897A5 (en) * 1983-10-11 1988-08-31 Fidia Spa NON-INFLAMMATORY HYALURONIC ACID FRACTIONS, PHARMACEUTICAL METHODS AND COMPOSITIONS.
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility

Also Published As

Publication number Publication date
HUT76846A (en) 1997-12-29
AP618A (en) 1997-10-10
AP9500756A0 (en) 1995-10-31
JPH10504828A (en) 1998-05-12
WO1996006622A1 (en) 1996-03-07
KR970705401A (en) 1997-10-09
CN1130532A (en) 1996-09-11
AU3159595A (en) 1996-03-22
EP0778776A1 (en) 1997-06-18

Similar Documents

Publication Publication Date Title
IL114914A0 (en) Modulation of cellular activity
GB2324919B (en) Modulation and frequency conversion by time sharing
HU9702034D0 (en) Heterocyclic compounds of leukocita-adhesion-inhibitor and vla-4-antagonist activity
PL318295A1 (en) Disposable cellular telephone
ZA954656B (en) High activity polyethylene catalysts
GB2294169B (en) Modulation and frequency conversion by time sharing
IL133822A0 (en) Aroylpiperazines for modulating sexual activity
HU9702242D0 (en) Inozitol-glykanes of inzulin-like activity
SG79882A1 (en) Protein having tpo activity
EP0687940A3 (en) Quasi-phasematched frequency converters
PL332904A1 (en) Dihydropyrones of improved antiviral activity
EP1011654A4 (en) A method of modulating cellular activity
PL327732A1 (en) Compounds of therapeutic activity
HU9700071D0 (en) Use of muramilpeptides
GB2289852B (en) Mobile
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
ZA957223B (en) Modulation of cellular activity
PL311885A1 (en) Protein of tpo activity
PL317319A1 (en) Oxidative amonolysis of alkylopyridines
ZA989413B (en) Determination of cellular growth abnormality
GB9724134D0 (en) Determination of cellular growth abnormality
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
IL114944A0 (en) Disposable cellular phone-set
GB9215053D0 (en) Enzyme catalyst